Our observation, that growth of TNBC is stimulated by 17β-estradiol via GPR30 indicates that reduction of 17β-estradiol in TNBC patients by application of aromatase inhibitors might remain a therapeutic option in triple-negative breast cancer. The gene discussed is GPER1; the disease is triple-negative breast carcinoma.